Summit Therapeutics plc
("Summit" or the "Company")
DIRECTOR SHARE DEALING
Oxford, UK, 18 June 2015 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Company has been notified that Ms Valerie Andrews, Non-Executive Director of the Company, has on 17 June 2015 bought 2,100 of American Depositary Shares ('ADSs') of Summit at a price of $11.50 per ADS.
Following this notification Ms Andrews beneficial interest in Summit shares is 2,100 ADSs (equivalent to 10,500 ordinary shares on 1p nominal value), representing approximately 0.02% of the Company's current issued share capital.
The ADSs were acquired on the NASDAQ Global Market. This notification relates to disclosures made in accordance with Rule 17 Schedule 5 of the AIM Rules.
- END -
For more information, please contact:
| Summit Therapeutics Richard Pye (UK office) Erik Ostrowski (US office) | Tel: +44 (0)1235 443 951 +1 617 294 6607 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |